5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen

Susan O'Brien, Joseph O. Moore, Thomas E. Boyd, Loree M. Larratt, Aleksander B. Skotnicki, Benjamin Koziner, Asher A. Chanan-Khan, John F. Seymour, John Gribben, Loretta M. Itri, Kanti R. Rai

Research output: Contribution to journal › Article › peer-review

125 Scopus citations

Fingerprint

Dive into the research topics of '5-Year survival in patients with relapsed or refractory chronic lymphocytic leukemia in a randomized, phase III trial of fludarabine plus cyclophosphamide with or without oblimersen'. Together they form a unique fingerprint.

Medicine & Life Sciences